Nitinotes Achieves CE Mark Approval for EndoZip
The approval marks a significant advancement in obesity treatment
In a pivotal moment for medical innovation, Nitinotes Ltd., a leading medical device company focused on transforming obesity treatment, has successfully received CE Mark approval for the EndoZip™ System. This achievement signifies the introduction of the first fully automated suturing platform specifically designed for endoscopic sleeve gastroplasty (ESG). As a result, Nitinotes is poised to launch this groundbreaking technology throughout the European Union and other markets that accept CE Mark regulations.
Obesity has emerged as one of the most critical health challenges globally, impacting over 650 million adults. The existing treatment options create a considerable gap between conservative approaches, like GLP-1 therapies, and invasive bariatric surgeries. Endoscopic sleeve gastroplasty is becoming increasingly recognized as a viable, minimally invasive solution, particularly for those with a Body Mass Index (BMI) ranging from 30 to 40 kg/m², who have struggled with traditional weight management strategies involving diet, exercise, or medicinal interventions.
EndoZip is revolutionizing the ESG procedure by automating suturing, thus allowing it to be performed rapidly in an outpatient setting by a single physician. Current manual suturing techniques often require two physicians, extended procedure durations, and advanced endoscopic expertise. EndoZip stands out with its efficiency, reliability, and cost-effectiveness, effectively broadening access to ESG and enhancing the capabilities of bariatric surgeons while establishing a new benchmark in patient care.
"The CE Mark approval of EndoZip is a critical milestone for Nitinotes," stated Lloyd Diamond, the Chief Executive Officer. "This decision underscores the safety and effectiveness of our technology and lays the groundwork for our launch in Europe. With EndoZip, we can significantly increase patient access to safe and durable obesity treatments while offering substantial benefits to healthcare providers and systems."
Following the CE Mark approval, Nitinotes plans to unveil EndoZip at select leading clinical centers across Europe. This initiative aims to foster clinical adoption and collect real-world data that can support broader market penetration. Meanwhile, the company is preparing for a pivotal U.S. Investigational Device Exemption (IDE) trial, which will facilitate FDA approval and entry into the largest obesity treatment market in the world.
About Nitinotes
Nitinotes is a privately owned medical device firm pioneering solutions for obesity treatment. The company's premier product, EndoZip™, represents a fully automated ESG system. It is specifically developed to provide a consistent, minimally invasive alternative to traditional bariatric surgery for patients classified as Class I and II obesity.
Nitinotes continues to push the boundaries of innovation in the medical field by providing an efficient and effective treatment for obesity, an issue that affects millions globally. For anyone looking for additional details about Nitinotes and the EndoZip™ system, visit their official website.
Media Contact:
Offer Nonhoff
Chief Financial Officer
SOURCE Nitinotes
Frequently Asked Questions
What is the significance of the CE Mark approval for EndoZip?
The CE Mark approval allows Nitinotes to commercialize EndoZip across Europe, marking a milestone in obesity treatment options.
How does EndoZip improve the ESG procedure?
EndoZip automates the suturing process, allowing it to be performed by a single physician, reducing the procedure time and complexity.
What advantage does EndoZip offer over traditional methods?
This innovative system enhances efficiency, reproducibility, and democratizes access to bariatric surgery, setting a new care standard.
What are the next steps for Nitinotes after receiving CE Mark approval?
Nitinotes plans to launch EndoZip in select European centers, collect clinical data, and prepare for a U.S. IDE trial.
What is the primary objective of Nitinotes?
Nitinotes aims to provide innovative solutions for the treatment of obesity, significantly expanding patient access to effective and safe procedures.
